WALTHAM, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced observational ...
The MarketWatch News Department was not involved in the creation of this content. -- Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to ...
JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced it ...
– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases – – Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion ...
Alnylam Scientists Present Pre-clinical Data with ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases – New Research Presented at 6 th ...
New data hub will accelerate development and adoption of human-based New Approach Methodologies The NYU Langone-Sage NDHCC will expand upon the work Sage Bionetworks has been doing for more than a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results